SUSAN IZZO: Open Payments
NPI 1881644631 · VERNON, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,522 in 190 payments from 39 companies in 2025. Trend: 2023 $3,992 · 2024 $3,994 · 2025 $3,522
Food & beverage: $3,498Education: $24
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 37 | $548 |
| AstraZeneca Pharmaceuticals LP | 14 | $321 |
| Vanda Pharmaceuticals Inc. | 13 | $240 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $228 |
| Otsuka America Pharmaceutical, Inc. | 8 | $173 |
| Amgen Inc. | 10 | $171 |
| PFIZER INC. | 11 | $169 |
| Lilly USA, LLC | 8 | $162 |
| Dexcom, Inc. | 7 | $149 |
| Novo Nordisk Inc | 9 | $144 |
Products named: VRAYLAR, REXULTI, FANAPT, CAPLYTA, Dexcom G6 Transmitter, MOUNJARO, BEVESPI AEROSPHERE, AIRSUPRA.
Industry payments across CT — which companies pay providers there.
